Lindsay Rein, MD, Duke University Medical Center, Durham, NC, presents on bomedemstat, a lysine-specific demethylase 1 (LSD1) inhibitor, in essential thrombocythemia (ET) and polycythemia vera (PV). Dr Rein highlights Phase II data showing platelet count normalization in ET and hematocrit control in PV, with manageable, mostly low-grade adverse events including dysgeusia, arthralgia, and GI symptoms, and mentions ongoing Phase III and Phase II/III trials. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.